Nachrichten und Videos - NEURALSTEM INC.

...

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases PR Newswire GERMANTOWN, Md., Oct. 30, 2019 GERMANTOWN, Md. , Oct. 30, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (fka Neuralstem, Inc.) (NASDAQ: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, and Jiangsu QYuns Therapeutics Co., Ltd., a China -based company focused on monoclonal antibody...

Neuralstem Becomes Seneca Biopharma PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md. , Oct. 28, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ:CUR), announces that the company has changed its name to Seneca Biopharma, Inc. The company anticipates that its shares will begin trading on the NASDAQ Capital Market under the symbol SNCA on November 1, 2019 or shortly thereafter subject to the satisfaction of customary conditions of the exchange. Concurrently with the name change, Seneca has...

Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4) PR Newswire GERMANTOWN, Md., Oct. 3, 2019 GERMANTOWN, Md. , Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced the adjustment of an options award that was previously approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 18,...

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR Newswire GERMANTOWN, Md., Sept. 24, 2019 GERMANTOWN, Md. , Sept. 24, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke. NSI-566 is...

Neuralstem Reports Second Quarter 2019 Fiscal Results PR Newswire GERMANTOWN, Md., Aug. 14, 2019 GERMANTOWN, Md. , Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019 . RECENT HIGHLIGHTS & ACCOMPLISHMENTS : Appointed Mary Ann Gray , Ph.D., to Board of Directors Executed...

Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing PR Newswire GERMANTOWN, Md., Aug. 7, 2019 GERMANTOWN, Md. , Aug. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the Company") today announced that on August 6, 2019 , it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing of the...

Neuralstem Closes $7.5 Million Underwritten Public Offering PR Newswire GERMANTOWN, Md., July 31, 2019 GERMANTOWN, Md. , July 31, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in gross proceeds of approximately $7,500,000 , before deducting discount, commissions and estimated offering expenses. Each unit...

Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering PR Newswire GERMANTOWN, Md., July 25, 2019 GERMANTOWN, Md. , July 25, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit for gross proceeds of approximately $7,500,000 , before deducting discount and commissions and estimated offering expenses. Each...

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors PR Newswire GERMANTOWN, Md., July 18, 2019 GERMANTOWN, Md. , July 18, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that Mary Ann Gray , Ph.D. has been appointed to the Company's Board of Directors. "We are pleased to welcome Mary Ann to our board, her expertise and...

Neuralstem Announces a 1-for-20 Reverse Stock Split PR Newswire GERMANTOWN, Md., July 16, 2019 GERMANTOWN, Md. , July 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17, 2019 after market close and shares of Neuralstem Inc. common stock...

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR Newswire GERMANTOWN, Md., July 1, 2019 GERMANTOWN, Md. , July 1, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial...

Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells PR Newswire GERMANTOWN, Md., May 16, 2019 GERMANTOWN, Md. , May 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the expansion of their intellectual property portfolio with the recent issuance of a newly published patent. U.S. Patent No. 10,286,010, entitled "Methods of Treating...

Neuralstem Reports First Quarter 2019 Fiscal Results - Kenneth C. Carter, PhD appointed Executive Chairman - Strategic initiative to expand pipeline announced PR Newswire GERMANTOWN, Md., May 14, 2019 GERMANTOWN, Md. , May 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, reported its financial results for the first quarter ended March...

Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors PR Newswire GERMANTOWN, Md., May 6, 2019 GERMANTOWN, Md. , May 6, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that David J. Mazzo , Ph.D. has been appointed to the Company's Board of Directors to be effective June 12, 2019 . Dr. Mazzo will replace Stanley Westreich ,...

Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies PR Newswire GERMANTOWN, Md., Feb. 7, 2019 GERMANTOWN, Md. , Feb. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the development of cell-based and small molecular therapeutic for central nervous system indications, today announced the initiation of a program to expand its current pipeline of therapeutic...

...

...

...

...